Search results

brentuximab (Adcetris)

For the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

brentuximab vedotin (Adcetris)

In combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).

brentuximab vedotin (Adcetris)

Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.

brentuximab vedotin (Adcetris)

Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.

brentuximab vedotin (Adcetris)

For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

brentuximab vedotin (Adcetris)

Treatment of adult patients with previously untreated cell membrane receptor 30-positive (CD30+) Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).

pembrolizumab (Keytruda)

monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.

nivolumab (Opdivo)

For the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

mogamulizumab (Poteligeo)

For the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.

October 2014 decisions news release

The Scottish Medicines Consortium (SMC), whose purpose is to review newly licensed medicines, today announced that nine new medicines have been accepted for use in NHSScotland.

January 2020 decisions news release

Medicines which can be used to treat prostate cancer, primary progressive multiple sclerosis, a rare form of lymphoma and migraine have today (Monday 13 January) been accepted by the Scottish Medicines Consortium (SMC) for use by NHSScotland.

January 2021 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 18 January) published advice accepting five new medicines.